Weekly XXXX with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced @entity189 .

@entity1 @entity137 @entity900 @entity1311 @entity189
PURPOSE: To evaluate the efficacy and @entity137 of weekly @entity1311 with concurrent radiotherapy followed by adjuvant chemotherapy (AC) in @entity1 with locally advanced @entity189 ( @entity189 ). METHODS AND MATERIALS: Between 2004 and 2007, 54 @entity1 with locally advanced @entity189 were included in this protocol. @entity1 CHARACTERISTICS: median age 48; 69% male; 52% World Health Organization (WHO) III; 50% stage III, 50% stage IV. The @entity1 underwent a course of definitive conventional radiotherapy (70 Gy in 7 weeks with 2 Gy/fraction), with concurrent weekly @entity1311 35 mg/m(2) from the first to the sixth week of radiation. AC was started 4 weeks after the end of the radiotherapy (RT), @entity1311 135 mg/m(2) on day 1 and @entity900 30 mg/m(2) on days 1-3 were administered every 4 weeks for two cycles. RESULTS: Median follow-up was 32 months. Eighty-five percentage of complete response and 15% partial response were achieved at the time of one month after AC. The 3-year actuarial rate of local regional control was 86%; distant metastases-free survival, progression-free survival and overall survival at 3 years were 81%, 69% and 76%, respectively. Forty-nine (91%) @entity1 completed six courses of concurrent chemotherapy with weekly @entity1311 , and 4 (7%) @entity1 delayed at the second cycle of AC. No @entity1 developed severe acute @entity137 . CONCLUSIONS: Weekly @entity1311 with concurrent RT followed by AC is a potentially effective and @entity137 tolerable method for locally advanced @entity189 . Further studies are needed to identify the optimal dose of weekly @entity1311 in this strategy.
